(Q37317810)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

review article

1 reference

title

CYP17 inhibition as a hormonal strategy for prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

Alison Hm Reid

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Elaine Barrie

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Johann S de Bono

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

language of work or name

English

0 references

publication date

1 November 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

published in

Nature Reviews Urology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

610-620

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/ncpuro1237

25 December 2019

exact match

0 references

cites work

Modulation of the activity of human 17 alpha-hydroxylase-17,20-lyase (CYP17) by cytochrome b5: endocrinological and mechanistic implications

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

The current state of hormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Drug insight: role of the androgen receptor in the development and progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Contribution of the androgen receptor to prostate cancer predisposition and progression

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Expression, structure, and function of androgen receptor in advanced prostatic carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Molecular determinants of resistance to antiandrogen therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

The androgen axis in recurrent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Aromatase inhibition: translation into a successful therapeutic approach

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

The use of computational chemistry in the study of sex steroid biosynthesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

The genetics, pathophysiology, and management of human deficiencies of P450c17.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Cross-resistance to different aromatase inhibitors in breast cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Aromatase inhibitors in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Treating prostate cancer: a rationale for targeting local oestrogens

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Aromatase mRNA levels in benign prostatic hyperplasia and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Selective aromatase inhibition for patients with androgen-independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

A molecular model for the enzyme cytochrome P450(17 alpha), a major target for the chemotherapy of prostatic cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P45017 alpha) with resistance to esterase hydrolysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

3- and 4-pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P450(17 alpha) (17 alpha-hydroxylase/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Synthesis and evaluation of 17-aliphatic heterocycle-substituted steroidal inhibitors of 17alpha-hydroxylase/C17-20-lyase (P450 17)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Novel steroidal pyrimidyl inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase).

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Inhibition of enzymes of estrogen and androgen biosynthesis by esters of 4-pyridylacetic acid

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Pyridyl substituted benzocycloalkenes: new inhibitors of 17 alpha-hydroxylase/17,20-lyase (P450 17 alpha)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

4,5-Dihydro-3-(2-pyrazinyl)naphtho[1,2-c]pyrazole: a potent and selective inhibitor of steroid-17 alpha-hydroxylase-C17,20-lyase (P450 17)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Novel imidazolyl and triazolyl substituted biphenyl compounds: synthesis and evaluation as nonsteroidal inhibitors of human 17alpha-hydroxylase-C17, 20-lyase (P450 17)

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

P450-dependent enzymes as targets for prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO1237

7 January 2021

Identifiers

DOI

10.1038/NCPURO1237

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18985049%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference